{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:38:19Z","timestamp":1793129899032,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104832","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:51:42Z","timestamp":1791442302000},"page":"104832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blockbuster drugs and forecast accuracy: How sponsor type is associated with commercial success of FDA-approved medicines"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5041-4027","authenticated-orcid":false,"given":"Michael R.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8634-2893","authenticated-orcid":false,"given":"Kevin","family":"Murgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-3553","authenticated-orcid":false,"given":"Tyler","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Dimakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104832_b0005","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/d41573-024-00068-6","article-title":"Efficiency, effectiveness and productivity in pharmaceutical R&D","volume":"23","author":"Roland","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/d41573-022-00213-z","article-title":"The significance of blockbusters in the pharmaceutical industry","volume":"22","author":"Schuhmacher","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103789","article-title":"Is the blockbuster imperative broken?","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104832_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104306","article-title":"A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104832_b0025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nrd4164","article-title":"Does size matter in R&D productivity? If not, what does?","volume":"12","author":"Ringel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrd4127","article-title":"Pharmaceutical forecasting: throwing darts?","volume":"12","author":"Cha","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/d41573-023-00063-3","article-title":"Herding in the drug development pipeline","volume":"22","author":"Fougner","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104832_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104610","article-title":"2025 in review: trends in pharmaceutical innovation","volume":"31","author":"Kinch","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104832_b0050","series-title":"Burger\u2019s Medicinal Chemistry and Drug Discovery","article-title":"FDA-approved medicines","author":"Kinch","year":"2021"},{"key":"10.1016\/j.drudis.2026.104832_b0055","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/14737167.2025.2507426","article-title":"Economic and developmental impacts of FDA designations: a systematic review and meta-analysis","volume":"25","author":"Williamson","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.drudis.2026.104832_b0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","article-title":"Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy","volume":"25","author":"Michaeli","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.drudis.2026.104832_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104508","article-title":"Therapeutic value and regulatory characteristics of breakthrough therapy drugs in the USA and China (2021\u20132023): a retrospective cohort study","volume":"30","author":"Mao","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104832_b0070","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/acs.jmedchem.3c02165","article-title":"A drug discovery perspective on FDA expedited development and incentive programs","volume":"67","author":"Brown","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104832_b0075","series-title":"Burger\u2019s Medicinal Chemistry, Drug Discovery and Development","article-title":"A primer for new product planning and forecasting in early-phase pharmaceutical development","author":"Draper","year":"2025"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:21:06Z","timestamp":1793128866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002370"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104832","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockbuster drugs and forecast accuracy: How sponsor type is associated with commercial success of FDA-approved medicines","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104832"}}